ARTICLE | Company News
Oncology Venture, Topotarget deal
November 19, 2012 8:00 AM UTC
Newco Oncology Venture debuted and acquired exclusive, worldwide rights from Topotarget to APO010, a recombinant fusion protein drug consisting of three human Fas ligands (TNF superfamily, member 6; ...